TELA Bio, Inc. (NASDAQ: TELA) reported Q4 EPS of ($0.53), $0.11 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $17 million versus the consensus estimate of $16.39 million.

For earnings history and earnings-related data on TELA Bio, Inc. (TELA) click here.